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Abstract
Background Rheumatoid arthritis (RA) is a chronic,
inflammatory and systemic autoimmune disease that leads to
progressive cartilage destruction. Advances in the treatment of
RA-related destruction of cartilage require profound insights
into the molecular mechanisms involved in cartilage
degradation. Until now, comprehensive data about the
molecular RA-related dysfunction of chondrocytes have been
limited. Hence, the objective of this study was to establish a
standardized  in vitro model to profile the key regulatory
molecules of RA-related destruction of cartilage that are
expressed by human chondrocytes.
Methods Human chondrocytes were cultured three-
dimensionally for 14 days in alginate beads and subsequently
stimulated for 48 hours with supernatants from SV40 T-antigen
immortalized human synovial fibroblasts (SF) derived from a
normal donor (NDSF) and from a patient with RA (RASF),
respectively. To identify RA-related factors released from SF,
supernatants of RASF and NDSF were analyzed with antibody-
based protein membrane arrays. Stimulated cartilage-like
cultures were used for subsequent gene expression profiling
with oligonucleotide microarrays. Affymetrix GeneChip
Operating Software and Robust Multi-array Analysis (RMA)
were used to identify differentially expressed genes. Expression
of selected genes was verified by real-time RT-PCR.
Results Antibody-based protein membrane arrays of synovial
fibroblast supernatants identified RA-related soluble mediators
(IL-6, CCL2, CXCL1–3, CXCL8) released from RASF.
Genome-wide microarray analysis of RASF-stimulated
chondrocytes disclosed a distinct expression profile related to
cartilage destruction involving marker genes of inflammation
(adenosine A2A receptor,  cyclooxygenase-2), the NF-κB
signaling pathway (toll-like receptor 2,  spermine synthase,
receptor-interacting serine-threonine kinase 2), cytokines/
chemokines and receptors (CXCL1–3,  CXCL8,  CCL20,
CXCR4,  IL-1β,  IL-6), cartilage degradation (matrix
metalloproteinase (MMP)-10, MMP-12) and suppressed matrix
synthesis (cartilage oligomeric matrix protein,  chondroitin
sulfate proteoglycan 2).
Conclusion Differential transcriptome profiling of stimulated
human chondrocytes revealed a disturbed catabolic–anabolic
homeostasis of chondrocyte function and disclosed relevant
pharmacological target genes of cartilage destruction. This
study provides comprehensive insight into molecular regulatory
processes induced in human chondrocytes during RA-related
destruction of cartilage. The established model may serve as a
human  in vitro disease model of RA-related destruction of
cartilage and may help to elucidate the molecular effects of anti-
rheumatic drugs on human chondrocyte gene expression.
ADORA2A = adenosine A2A receptor; BCL2A1 = BCL2-related protein A1; CMKOR = chemokine orphan receptor; COMP = cartilage oligomeric 
matrix protein; COX = cyclooxygenase; CSPG = chondroitin sulfate proteoglycan; ECM = extracellular matrix; GCOS = GeneChip Operating Soft-
ware; Gro = growth-related oncogene; IFI-6–16 = interferon-α inducible protein-6–16; IL = interleukin; MCP = monocyte chemoattractant protein; 
MMP = matrix metalloproteinase; NDSF = synovial fibroblast cell line derived from normal donor; NDSFsn = supernatant of NDSF; NF = nuclear 
factor; OAS1 = 2',5'-oligoadenylate synthetase 1; PGES = prostaglandin E synthase; RA = rheumatoid arthritis; RASF = synovial fibroblast cell line 
derived from patient with RA; RASFsn = supernatant of RASF; RIPK = receptor-interacting serine/threonine kinase; RMA = Robust Multi-array Anal-
ysis; RT-PCR = polymerase chain reaction with reverse transcription; SF = synovial fibroblasts; SMS = spermine synthase; STAT = signal transduc-
tion and activators of transcription; STS = steroid sulfatase; THBS = thrombospondin; TLR = toll-like receptor; TNF = tumor necrosis factor; TXNIP 
= thioredoxin interacting protein.Arthritis Research & Therapy    Vol 10 No 1    Andreas et al.
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Introduction
Rheumatoid arthritis (RA) is an inflammatory disease charac-
terized by a chronic inflammation of synovial joints that leads
to a progressive destruction of articular and periarticular struc-
tures, causing severe morbidity and disability [1]. In RA, the
extensive infiltration of inflammatory cells into the synovium
and the tumor-like proliferation of RA synovial fibroblasts
(RASF) cause the formation of a hyperplastic pannus, which
aggressively invades and destroys underlying cartilage and
bone. Until now, the role of macrophages, T and B cells, neu-
trophils and RASF in the pathophysiology of RA have been
examined extensively [2-6]. Because RASF are known to be
one of the key mediators of cartilage destruction in RA [3],
comprehensive data have emerged in recent years from gene
expression analyses identifying diagnostically and therapeuti-
cally highly valued pathophysiological targets of RASF that
mediate joint destruction and inflammation [7-9]. Basically, the
underlying pathophysiological mechanisms of RASF involve
direct cartilage destruction such as infiltration and proteolytic
matrix digestion [3,10] and indirect mechanisms triggered by
IL-1β and TNF-α, which are secreted from RASF and shift car-
tilage homeostasis towards catabolism [11]. However, com-
prehensive data on these indirect effects of RASF mediators
on the molecular function of chondrocytes – the single cell
type that entirely conducts the cartilage remodeling process –
are limited and the underlying molecular pathways still need to
be determined thoroughly.
So far, important insights into the mechanisms of RA-related
destruction of cartilage have already been obtained from sev-
eral animal models of arthritis, including destructive arthritis
induced by various antigens, transgenic and mutation models
and immunodeficient mice [12-16]. In these studies, RA-medi-
ated cartilage destruction was analyzed by histological stain-
ing, radiological analysis, and magnetic resonance imaging,
which may not reveal the molecular modes of action during
cartilage and/or chondrocyte damage in RA. Apart from the
challenging molecular examination of cartilage characteristics
in vivo, the extrapolation of data gained from animal models to
the human situation in vivo is difficult, thus limiting direct con-
clusions. Animal models are very complex and cost-intensive
systems evoking moral and ethical concerns. According to the
'3Rs' concept defined by Russell and Burch in 1959 [17],
namely that all efforts to replace, reduce and refine experi-
ments must be undertaken, special attention being given to the
development and validation of alternatives (for example in vitro
models) to animal testing. Tissue engineering offers the oppor-
tunity to develop complex physiological in vitro models reflect-
ing human significance under well-defined and reproducible
conditions. Thus, the objective of the present study was to
establish a standardized in vitro model to profile the key regu-
latory molecules expressed by human chondrocytes that are
involved in RA-related destruction of cartilage.
Because mature human articular cartilage has a low cell den-
sity, expansion of harvested primary chondrocytes was
required to obtain sufficient cell numbers, but this led to ded-
ifferentiation of the chondrogenic phenotype. We therefore
cultured expanded human articular chondrocytes in alginate
beads for 14 days. The alginate bead culture is known to
mimic the three-dimensional environment of the cartilage
matrix and to preserve the chondrocyte phenotype even in
long-term cultures [18]. Furthermore, expanded chondrocytes
restore the differentiated phenotype in alginate culture and
develop a typical catabolic response to IL-1β after 2 weeks of
cultivation, indicating the relevance of the alginate culture to
the study of chondrocyte biology on proinflammatory stimulus
[19]. Contemporary studies on alginate culture showed that
expanded chondrocytes cultured in alginate retain chondro-
cyte gene expression but the expression level is reduced from
the cells' native phenotype; it is therefore not possible to
achieve a complete re-differentiation of expanded chondro-
cytes [20,21]. However, the alginate bead culture was chosen
for reasons of standardization; it offers the opportunity (1) to
culture expanded chondrocytes batchwise in a phenotype-sta-
bilizing environment, (2) to stimulate chondrocytes batchwise
with soluble mediators released from NDSF and RASF,
respectively, and (3) to determine the gene expression profile
of stimulated chondrocytes by microarray analysis after the
isolation of chondrocytes from the alginate.
For reasons of availability, comparability and standardization,
human SV40 T-antigen immortalized synovial fibroblasts (SF)
derived from a patient with RA (RASF) and from a normal
donor (NDSF) were used. Previous studies determined the
NDSF cell line to normal healthy synovial fibroblasts that
express typical cell surface molecules, maintain the normal
expression kinetics of early growth response 1 on stimulation
by synovial fluid from patients with RA or by TNF-α and induce
the HLA-DR expression in response to interferon-γ [22]. The
RASF cell line was determined as a prototype of activated syn-
ovial fibroblasts. Genome-wide microarray analysis of RASF
compared with NDSF revealed an induced expression of
genes associated with the pathomechanism of RA including
IL-1α, IL-1β, IL-8 and CXCL3, and treatment of RASF with fre-
quently used anti-rheumatic drugs reverted the expression of
numerous RA-related genes that were associated with cell
growth, metabolism, apoptosis, cell adhesion, and inflamma-
tion [23]. Additionally, RASF were shown to synthesize, at the
protein level, increased amounts of numerous inflammatory
cytokines and matrix-degrading enzymes [23,24].
In brief, our investigation sought to determine the key regula-
tory molecules of chondrocyte dysfunction that are associated
with cartilage destruction in RA. For this purpose, a standard-
ized in vitro model of RA-related destruction of cartilage was
established. In this model, human chondrocytes were cultured
in alginate beads and stimulated with soluble mediators
secreted from NDSF and RASF, respectively. Genome-wideAvailable online http://arthritis-research.com/content/10/1/R9
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differential expression profiling of stimulated chondrocytes
was subsequently performed, and expression of selected
genes was validated by real-time RT-PCR.
Materials and methods
Human chondrocyte isolation and cultivation
The local ethical committee of the Charité Berlin approved this
study.
For chondrocyte isolation, human articular chondrocytes from
six normal donors post mortem without obvious joint defects
and macroscopic signs of osteoarthritis were isolated from the
medial and lateral condyle of femur bones obtained from the
Institute of Pathology at the Charité University Hospital Berlin.
The average patient age was 60 years, ranging from 39 to 74
years. Chondrocytes were harvested as described previously
[25] and expanded in monolayer culture with RPMI 1640
medium (Biochrom, Berlin, Germany) supplemented with 10%
human serum, 100 ng/ml amphotericin B (Biochrom), 100 U/
ml penicillin and 100 μg/ml streptomycin (Biochrom).
Throughout the experiment, the same pool of human serum (n
= 5 donors) was used. Medium was changed every 2 to 3
days. Reaching subconfluence, chondrocytes were detached
with 0.05% trypsin and 0.02% EDTA (Biochrom) and cryopre-
served. After cryopreservation, human chondrocytes were
expanded in a monolayer and, after reaching subconfluence
again, the cells were trypsinized and subsequently immobilized
in alginate beads.
Cultivation of synovial fibroblasts
Human SV40 T-antigen immortalized SF were derived from a
patient with RA (HSE cell line; RASF) and from a normal donor
(K4IM cell line; NDSF), respectively. Synovial pannus tissue
from a patient with RA was obtained by surgical synovectomy
of the knee joint from a patient diagnosed according to the
American College of Rheumatology revised criteria as having
active RA [26]. Normal donor synovial tissue was obtained
during meniscectomy from a 41-year old male suffering from a
meniscus lesion [22]. After isolation of the human synovial
fibroblasts, the cells were transfected with SV40 TAg expres-
sion vector, yielding immortalized synovial fibroblast cell lines
[22,26]. Immortalized synovial fibroblasts derived from the
patient with RA represent RASF, and immortalized synovial
fibroblasts derived from the normal donor patient represent
NDSF. SF were expanded in a monolayer with RPMI 1640
medium supplemented with 10% human serum, 100 U/ml
penicillin and 100 μg/ml streptomycin. Medium was changed
every 2 to 3 days.
Preparation of alginate bead culture and interactive in 
vitro model
Alginate (Sigma, Taufkirchen, Germany) solution was pre-
pared in 150 mM NaCl and 30 mM HEPES at 3% (w/v) and
sterilized by autoclaving. Equal volumes of alginate solution
and human articular chondrocyte suspension were combined
to yield suspensions with final cell densities of 2 × 107 cells/
ml in 1.5% (w/v) alginate. Spherical beads were created by
dispensing droplets of alginate cell suspension from the tip of
an 18-gauge needle into a bath of 120 mM CaCl2, 10 mM
HEPES, 0.01% Tween 80 and 150 mM NaCl followed by
gelation for 20 minutes. Beads were cultured in batches in six-
well plates for 2 weeks in RPMI 1640 medium supplemented
with 10% human serum, 100 ng/ml amphotericin B, 100 U/ml
penicillin, 100 μg/ml streptomycin and 170 μM l-ascorbic acid
2-phosphate (Sigma).
Medium of NDSF and RASF at 80% confluence was condi-
tioned for 48 hours, and supernatants were adjusted to the
same ratio of volume/cell number and stored at -20°C. After 2
weeks of three-dimensional chondrocyte cultivation in alginate
beads, medium of cartilage-like beads was replaced by col-
lected supernatants of NDSF (NDSFsn) or RASF (RASFsn).
Interactive cultivation was performed for 48 hours (Figure 1).
To determine baseline gene expression, a control group of
alginate-embedded chondrocytes was treated with cultivation
medium for 48 hours.
RNA purification
Total RNA from stimulated cartilage-like alginate beads was
extracted with RNeasy Mini Kit (Qiagen, Hilden, Germany) in
Figure 1
Experimental setup Experimental setup. Human articular chondrocytes were isolated from 
six normal donors post mortem and expanded in monolayer culture. 
After cryopreservation and a second monolayer expansion, the cells 
were encapsulated in alginate beads and cultured three-dimensionally 
for 14 days. Subsequently, the cartilage-like beads were stimulated for 
48 hours with supernatants (sn) of SV40 T-antigen immortalized human 
synovial fibroblasts derived from a healthy, normal donor (NDSF) and 
from a patient with rheumatoid arthritis (RASF), respectively. Superna-
tants of RASF (RASFsn) and NDSF (NDSFsn) and medium control 
were analyzed for soluble mediators with the use of antibody-based 
protein membrane arrays. Genome-wide expression analyses of NDS-
Fsn-stimulated and RASFsn-stimulated chondrocytes were performed 
with oligonucleotide microarrays. Additionally, unstimulated chondro-
cytes were analyzed for baseline expression. Two independent experi-
ments (n = 2) were performed for NDSFsn-stimulated and RASFsn-
stimulated and unstimulated chondrocytes; each experimental group 
(G1, G2) consisted of chondrocytes derived from three different 
donors. Expression of selected differentially expressed genes was vali-
dated by real-time RT-PCR.Arthritis Research & Therapy    Vol 10 No 1    Andreas et al.
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accordance with the manufacturer's instructions. Before RNA
extraction, alginate beads were solubilized on ice in 55 mM
sodium citrate, 30 mM EDTA and 150 mM NaCl, and cells
were centrifuged at 800 g and 4°C for 5 minutes. Total RNA
isolation was conducted in accordance with the manufac-
turer's protocol. In addition, digestions with proteinase K and
DNase I (Qiagen) were performed.
Isolation of total RNA was performed for the six different stim-
ulated donor chondrocytes separately. Afterwards, equal
amounts of total RNA from three stimulated donor chondro-
cytes (1.5 μg from each donor) were pooled, yielding two dif-
ferent experimental groups of NDSFsn-stimulated and
RASFsn-stimulated chondrocytes and of unstimulated
chondrocytes. From each experimental group, 2.5 μg of com-
bined total RNA was used for microarray applications and 2
μg was used for real-time RT-PCR. Gene expression profiling
from pooled RNA samples derived from individual donors with
a reasonable replication of pooled arrays has recently been
determined to be statistically valid, efficient and cost-effective
[27,28].
Oligonucleotide microarrays
Microarray analyses of RASFsn-stimulated and NDSFsn-stim-
ulated chondrocytes and unstimulated chondrocytes were
performed for two experimental groups (n = 2). The Human
Genome U133A GeneChip (Affymetrix, High Wycombe, UK)
that determines the expression level of 18,400 transcripts and
variants representing about 14,500 human genes was used
for gene expression analysis. Microarray preparation was per-
formed in accordance with the manufacturer's protocol. In
brief, equal quantities of high-quality total RNA from experi-
mental groups (2.5 μg of each) were reverse transcribed to
single-stranded cDNA. After a second-strand cDNA synthesis,
biotin-labeled antisense cRNA was generated by in vitro tran-
scription. Next, 15 μg of each generated cRNA preparation
was fragmented and hybridized to the oligonucleotide micro-
array. Washing, staining and scanning were performed auto-
matically with the Affymetrix GeneChip System. Raw
expression data were analyzed using (1) GeneChip Operating
Software (GCOS) version 1.2 (Affymetrix) in accordance with
the manufacturer's recommendations and (2) Robust Multi-
array Analysis version 0.4α7 (RMA) [29]. Differentially
expressed genes reproducibly showed a fold change of ≤-2
(decrease) or a fold change of ≥2 (increase) as determined by
GCOS and RMA data processing. The filtered gene list was
functionally annotated with the use of reports from the litera-
ture. Hierarchical cluster analysis with signal intensity of differ-
entially expressed genes and the Pearson correlation distance
were performed with Genesis 1.7.2 software [30]. Microarray
data have been deposited in NCBIs Gene Expression Omni-
bus (GEO) and are accessible through GEO series accession
number GSE10024.
Real-time RT-PCR
Equal quantities of high-quality total RNA from both experimen-
tal groups (2 μg of each) of both NDSFsn-stimulated and RAS-
Fsn-stimulated chondrocytes were reverse transcribed with
iScript cDNA synthesis kit (Bio-Rad, Munich, Germany) in
accordance with the manufacturer's instructions. TaqMan real-
time RT-PCR was performed in triplicates in 96-well optical
plates on an ABI Prism 7700 Sequence Detection system
(Applied Biosystems, Darmstadt, Germany) with Gene Expres-
sion Assays for TaqMan probes and primer sets, which were
pre-designed and pre-optimized by Applied Biosystems. Quan-
titative gene expression was analyzed for chemokine (C-X-C
motif) receptor 4 (CXCR4, assay ID Hs00607978_s1), thiore-
doxin interacting protein (TXNIP, Hs00197750_m1), chondroi-
tin sulfate proteoglycan 2 (CSPG2, Hs00171642_m1), IFN-α
inducible protein-6–16 (IFI-6–16, Hs00242571_m1), cycloox-
ygenase-2  (COX-2, Hs00153133_m1), cartilage oligomeric
matrix protein (COMP, Hs00164359_m1), steroid sulfatase
(STS, Hs00165853_m1) and glyceraldehyde-3-phosphate
dehydrogenase (GAPDH, Hs99999905_m1). The expression
levels of selected differentially expressed genes were normal-
ized to endogenous glyceraldehyde-3-phosphate dehydroge-
nase expression level and calculated with the 2-ΔΔCt formula
(ABI Prism 777 Sequence Detection System User Bulletin no.
2). For statistical analysis, Students' ttest was applied.
Proteomic membrane array analysis
The human protein membrane array (RayBiotech, Norcross,
GA, USA) simultaneously profiles 30 custom proteins in dupli-
cate. Experiments were performed in accordance with the
manufacturer's instructions. In brief, conditioned supernatants
of both NDSF and RASF were adjusted with medium to the
same ratio of volume/cell number and stored at -20°C. Human
cytokine array membranes were incubated for 30 min in 2 ml
of blocking buffer and afterwards for 2 hours in 2 ml of sample
supernatant at 20°C. After being washed, the membranes
were incubated with biotin-conjugated antibodies (1:250 dilu-
tion; 1 ml per array membrane) at room temperature for 2
hours and washed again. A solution containing horseradish
peroxidase-conjugated streptavidin (1:1,000 dilution; 2 ml)
was added and incubation was continued for 2 hours followed
by a third washing step. Proteins were detected by enhanced
chemiluminescence and the membranes were briefly exposed
to X-ray films (Amersham, Munich, Germany) for 30 s, 1 min, 2
min and 4 min. Array images were acquired at a resolution of
300 d.p.i. on a computer photo scanner.
Results
Gene expression profiling of stimulated chondrocytes
Because the progressive destruction of articular cartilage is a
prominent feature of RA and numerous molecular properties of
RASF contributing to cartilage degradation have already been
studied, we sought to elucidate cartilage destruction on the
basis of chondrocyte gene expression patterns that were
induced by soluble mediators secreted from RASF. For thisAvailable online http://arthritis-research.com/content/10/1/R9
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purpose, an in vitro model was established that was com-
posed of human articular chondrocytes that had been encap-
sulated for 2 weeks in alginate beads and then stimulated for
48 hours with supernatant of RASF (RASFsn) or NDSF
(NDSFsn).
Alginate beads were generated reproducibly with a spherical
shape and a diameter of 2.13 ± 0.13 mm (data not shown).
Differential expression analysis of chondrocytes stimulated
with RASFsn and NDSFsn was used to determine molecular
RA-related patterns of chondrocyte gene expression. GCOS
and RMA statistical analyses showed 68 reproducibly differ-
entially expressed genes; 44 genes were induced (fold
change ≥ 2) and 24 genes were repressed (fold change ≤ -2).
The differentially expressed genes were functionally annotated
with reports from the literature and were classified into six
functional groups (Table 1). Visualization of these differentially
expressed genes by hierarchical clustering demonstrated that
the expression patterns of the corresponding experimental
groups for both RASFsn-stimulated and NDSFsn-stimulated
chondrocytes were similar to each other; corresponding
groups clustered and showed little degree of variability (Figure
2).
Basically, RASFsn-stimulated chondrocytes showed, in com-
parison with NDSFsn-stimulated chondrocytes, an altered
expression of genes associated with inflammation (NF-κB sig-
naling pathway, cytokines/chemokines and receptors, and
immune response) and cartilage destruction (matrix metallo-
proteinases (MMPs), chondrocyte apoptosis, and suppressed
matrix synthesis).
As shown in Table 1, genes related to inflammation were dif-
ferentially expressed in RASFsn-stimulated chondrocytes:
cyclooxygenase-2 (COX-2) and phospholipase A2 group IIA
(PLA2G2A) regulating the synthesis of prostaglandins, ade-
nosine A2A receptor (ADORA2A) as an important immuno-
modulator of inflammation, and steroid sulfatase (STS) and
hydroxysteroid (11-β) dehydrogenase 1 (HSD11B1), which
are involved in the biosynthesis of steroid hormones. Moreo-
ver, expression of several genes involved in the NF-κB signal-
ing pathway showed differential expression, including
interleukin-1 receptor antagonist (IL1RN), receptor-interact-
ing serine/threonine kinase 2 (RIPK2),  toll-like receptor 2
(TLR2),  spermine synthase (SMS),  thioredoxin interacting
protein  (TXNIP) and BCL2-related protein A1 (BCL2A1).
Apart from NF-κB-associated genes, some cytokines/chemok-
ines and receptors were induced, such as granulocyte colony-
stimulating factor 3 (CSF3), IL-23A and hepatocyte growth
factor receptor (Met), the chemokines CXCL1–3 (Groα–γ),
CXCL8  (IL-8) and CCL20  (MIP-3β), and the chemokine
receptor CXCR4.
Additionally, profiling of gene expression in RASFsn-stimu-
lated chondrocytes showed a repression of genes involved in
cell proliferation and differentiation, and a distinct induction of
numerous genes associated with immune response, including
2',5'-oligoadenylate synthetase 1 (OAS1),  2',5'-oligoade-
nylate synthetase-related protein p30 (OASL) and IFI-6–16.
Besides inflammation, RASFsn-stimulated chondrocytes
showed a distinct expression of genes associated with carti-
lage destruction, including chondrocyte apoptosis (BCL2A1,
RIPK2 and TLR2) and suppressed extracellular matrix (ECM)
synthesis; cartilage oligomeric matrix protein (COMP), chon-
droitin sulfate proteoglycan 2 (CSPG2) and thrombospondin
2  (THBS2) were repressed in RASFsn-stimulated
chondrocytes.
Apart from the 68 differentially expressed genes reaching a
fold change of ≥2 or ≤-2, the expression of already established
marker genes of cartilage destruction that failed to meet the
stringent twofold regulation criteria is listed in Table 2. How-
ever, these established RA-related genes showed also differ-
ential expression of at least 1.5-fold (GCOS data), including
genes involved in oxygen damage and IL-1β, IL-6, prostaglan-
din E synthase (PGES) and genes associated with NF-κB and
TNF-α. Moreover, the expression of the matrix-degrading
enzymes MMP10 and MMP12 was induced and the expres-
sion of testican-1 and genes encoding numerous collagens
was repressed.
Thus, genome-wide microarray data displayed differential
expression of distinct genes in human chondrocytes that have
already been implicated in inflammatory diseases or cartilage
destruction. However, several differentially expressed genes
have not yet been described as being regulated in chondro-
cytes during RA-related destruction of cartilage.
Validation of gene expression profiles by real-time RT-
PCR
The expression profiles of selected genes obtained by micro-
array analysis were verified by gene expression analysis with
real-time RT-PCR. Because numerous RA-relevant genes
were differentially expressed in RASFsn-stimulated chondro-
cytes, representative candidate genes associated with inflam-
mation and cartilage destruction were selected for validation.
Among these genes, COX-2, IFI-6–16 and STS were linked
with inflammation, and CSPG2, COMP, CXCR4 and TXNIP
were involved in matrix synthesis and cartilage destruction.
The expression profiles of COX-2,  IFI-6–16  and  CXCR4
showed a significant induction, and STS, CSPG2, COMP and
TXNIP  were significantly repressed in RASFsn-stimulated
chondrocytes compared with NDSFsn-treated controls (Fig-
ure 3), thus confirming the gene expression pattern identified
by microarray analysis.Arthritis Research & Therapy    Vol 10 No 1    Andreas et al.
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Figure 2
Hierarchical clustering and functional classification of differentially expressed genes Hierarchical clustering and functional classification of differentially expressed genes. Genome-wide expression analysis was performed for two differ-
ent experimental groups (G) of chondrocytes stimulated with supernatant of a synovial fibroblast cell line derived from a patient with rheumatoid 
arthritis (RASFsn) and chondrocytes stimulated with supernatant of a synovial fibroblast cell line derived from normal donor (NDSFsn) (n = 2). Each 
experimental group was a pool of RNA isolated from stimulated chondrocytes that originated from three different donors; that is, group 1 (G1) con-
sisted of equal amounts of RNA from stimulated chondrocytes of donors 1 to 3 and group 2 (G2) of donors 4 to 6. Genes that displayed ≥2-fold 
increase or ≤-2-fold decrease in RASFsn-stimulated compared with NDSFsn-stimulated chondrocytes determined by both analyses with GeneChip 
Operating Software and Robust Multi-array Analysis were hierarchically clustered and functionally classified into six groups. Colors represent relative 
levels of gene expression: bright red indicates the highest level of expression and bright green indicates the lowest level of expression. Expression 
data from the different experimental groups were compared and showed that the expression patterns were similar for the corresponding experimen-
tal groups of both RASFsn-stimulated and NDSFsn-stimulated chondrocytes because they clustered and were therefore most similar to each other, 
showing little variability.Available online http://arthritis-research.com/content/10/1/R9
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Table 1
Differentially expressed genes in RASFsn-stimulated chondrocytes (FC ≥ 2; FC ≤ -2; RMA and GCOS)
Functional annotation: gene title (gene 
symbol)
Accession no. Chondrocyte mean 
fold change in 
expression (GCOS 
and RMA analysis)
Chondrocyte mean signal intensity (GCOS and RMA 
analysis)
RASFsn versus 
NDSFsn stimulation
RASFsn stimulation NDSFsn stimulation No stimulation
Inflammation
Cyclooxygenase-2 (COX-2) NM_000963.1 2.09 4,474.90 1,793.25 108.4
Hydroxysteroid (11-β) dehydrogenase 1 
(HSD11B1)
NM_005525 2.41 2,693.41 955.89 1,263.95
Adenosine A2A receptor (ADORA2A) NM_000675 4.73 249.59 40.13 27.33
Phospholipase A2, group IIA (PLA2G2A) NM_000300 -2.38 152.32 347.63 787.68
Steroid sulfatase (STS) AI122754 -3.17 48.36 132.73 412.43
Latexin (LXN) NM_020169 -5.82 122.35 677.95 610.08
NF-κB signaling pathway
Interleukin-1 receptor antagonist (IL1RN) U65590 2.10 1,143.23 278.77 48.83
Receptor-interacting serine/threonine 
kinase 2 (RIPK2)
AF064824.1 2.12 1,190.60 539.58 22.65
Toll-like receptor 2 (TLR2) NM_003264 2.25 859.07 322.16 57.30
Spermine synthase (SMS) NM_004595 2.90 165.10 58.99 40.10
Bcl2-related protein A1 (BCL2A1) NM_004049 4.90 573.95 94.87 14.63
Ectonucleotide pyrophosphatase/
phosphodiesterase 2 (ENPP2)
L35594.1 -3.26 810.00 2,175.34 1,273.98
Thioredoxin interacting protein (TXNIP) AI439556 -3.50 223.27 622.39 670.70
Cytokines/chemokines and receptors
Met proto-oncogene (HGF receptor) 
(MET)
J02958.1 2.02 823.83 333.01 74.13
Chemokine (C-X-C motif) ligand 1 
(Groα)
NM_001511.1 2.08 1,414.49 478.28 28.05
Chemokine (C-X-C motif) ligand 2 
(Groβ)
M57731.1 2.51 761.47 237.34 10.08
Interleukin 8 (IL8) AF043337.1 3.16 5,688.87 1,393.65 38.28
Chemokine (C-X-C motif) ligand 3 
(Groγ)
NM_002090 3.78 368.84 58.19 16.68
Chemokine (C-C motif) ligand 20 (MIP-
3β)
NM_004591.1 5.25 2,028.88 270.12 14.65
Granulocyte colony-stimulating factor 3 
(CSF3)
NM_000759 5.61 180.70 51.59 45.18
Chemokine (C-X-C motif) receptor 4 
(CXCR4)
AJ224869 5.66 180.71 27.87 16.10
Interleukin-23, α subunit p19 (IL-23A) NM_016584 11.00 674.98 43.00 39.33
Immune responseArthritis Research & Therapy    Vol 10 No 1    Andreas et al.
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Guanylate binding protein 1, interferon-
inducible (GBP1)
BC002666 2.10 450.29 198.92 175.15
2',5'-Oligoadenylate synthetase-related 
protein p30 (OASL)
AF063612.1 2.38 287.65 98.51 115.65
Interferon-induced protein 44 (IFI44) NM_006417 2.40 480.29 124.50 238.30
Lymphocyte antigen 6 complex, locus E 
(LY6E)
NM_002346.1 2.45 569.07 236.97 305.15
Interferon regulatory factor 7 (IRF7) NM_004030.1 2.48 286.31 93.75 84.93
Interferon-α inducible protein (IFI-6–16) NM_022873 2.60 550.64 158.67 138.78
Interferon-stimulated gene 20 kDa 
(ISG20)
U88964 2.61 434.38 153.79 47.20
Interferon-induced protein with 
tetratricopeptide repeats 3 (IFIT3)
NM_001549 2.69 527.75 137.20 290.03
Pentaxin-related gene, rapidly induced 
by IL-1β (PTX3)
NM_002852 2.72 340.14 120.25 209.70
Hect domain and RLD 6 (HERC6) NM_017912.1 3.04 302.12 65.85 117.53
Myxovirus resistance 1, interferon-
inducible protein p78 (MX1)
NM_002462 3.09 1,355.03 312.35 557.75
Hect domain and RLD 5 (HERC5) NM_016323 3.30 608.65 160.90 141.13
2',5'-Oligoadenylate synthetase 1 
(OAS1)
NM_002534 4.08 264.81 55.57 70.00
Interferon-α inducible protein, clone IFI-
15K (ISG15)
NM_005101.1 4.62 1,943.31 296.19 603.98
Interferon-induced protein 44-like 
(IFI44L)
NM_006820.1 4.64 691.99 84.63 138.85
Interferon-α inducible protein 27 (IFI27) NM_005532 5.07 814.69 119.31 154.15
Interferon-induced protein with 
tetratricopeptide repeats 1 (IFIT1)
NM_001548 5.25 774.38 94.09 361.93
Viperin (cig5) AI337069 7.14 423.91 34.32 45.65
Collectin sub-family member 12 
(COLEC12)
NM_030781 -2.22 648.64 1,347.08 2,518.28
Cell proliferation and differentiation
WNT1 inducible signaling pathway 
protein 2 (WISP2)
NM_003881 -2.97 206.25 508.11 4,898.73
Inhibitor of DNA binding 3, dominant 
negative HLH protein (ID3)
NM_002167.1 -3.74 240.35 715.78 1,465.13
Inhibitor of DNA binding 1, dominant 
negative HLH protein (ID1)
D13889.1 -4.04 742.79 2,479.99 2,376.33
Retinoic acid receptor responder 1 
(RARRES1)
NM_002888 -6.10 115.83 538.71 152.20
Fibroblast growth factor 1, acidic 
(FGF1)
X59065 -8.51 82.49 513.38 70.23
Matrix synthesis
Laminin, β3 (LAMB3) L25541.1 3.05 636.22 196.21 63.28
Table 1 (Continued)
Differentially expressed genes in RASFsn-stimulated chondrocytes (FC ≥ 2; FC ≤ -2; RMA and GCOS)Available online http://arthritis-research.com/content/10/1/R9
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EGF-containing fibulin-like ECM protein 
1 (EFEMP1)
NM_004105 -3.14 170.34 458.87 331.85
Thrombospondin 2 (THBS2) NM_003247 -3.28 181.13 489.40 483.68
Spondin 1, extracellular matrix protein 
(SPON1)
AB051390.1 -4.4 56.04 167.4 69.60
Chondroitin sulfate proteoglycan 2 
(CSPG2)
NM_004385 -4.53 235.72 670.67 456.13
Cartilage oligomeric matrix protein 
(COMP)
NM_000095 -5.08 156.77 655.37 308.43
Others
Metallothionein 1E (MT1E) BF217861 2.03 1,111.45 554.65 708.38
Solute carrier family 7 member 11 
(SLC7A11)
AB040875.1 2.16 692.03 300.52 87.70
Deafness, autosomal dominant 5 
(DFNA5)
NM_004403 2.63 1,133.05 379.29 288.20
Phosphoglycerate dehydrogenase 
(PHGDH)
NM_006623 2.63 171.02 60.04 138.58
Paired immunoglobin-like type 2 
receptor α (PILRA)
AJ400843.1 2.82 131.89 32.78 23.75
Calmegin (CLGN) NM_004362.1 3.20 356.58 87.11 19.30
Neuromedin B (NMB) NM_021077 3.34 1,163.69 261.33 177.98
Regulator of G-protein signaling 4 
(RGS4)
NM_005613.3 3.92 136.81 22.34 42.05
Phosphoinositide-3-kinase, polypeptide 
1 (PIK3R1)
AI679268 -3.03 105.59 262.02 182.88
Deiodinase, iodothyronine, type II (DIO2) U53506.1 -3.10 71.24 193.23 122.88
DEAD (Asp-Glu-Ala-Asp) box 
polypeptide 10 (DDX10)
NM_004398.2 -3.22 223.36 681.54 252.50
CDK5 regulatory subunit associated 
protein 2 (CDK5RAP2)
NM_018249 -3.28 250.80 660.54 349.68
Cullin 4B (CUL4B) AV694732 -3.41 130.55 381.94 83.58
Pyruvate dehydrogenase kinase, 
isoenzyme 4 (PDK4)
NM_002612.1 -3.65 54.75 179.75 72.75
ATP-binding cassette, sub-family A 
(ABC1), member 8 (ABCA8)
NM_007168 -3.83 81.80 202.99 141.58
Adlican (DKFZp564I1922) AF245505.1 -4.90 145.69 486.56 1,835.15
Genes were selected for inclusion if fold change in expression of chondrocytes stimulated with supernatant of a synovial fibroblast cell line derived 
from a rheumatoid arthritis patient (RASFsn) was ≤-2 (repression) or ≥2 (induction) relative to stimulation with supernatant of a synovial fibroblast 
cell line derived from a normal donor (NDSFsn) in all specimens (n = 2) as verified by GeneChip Operating Software (GCOS) and Robust Multi-
array Analysis (RMA) analyses. Gene expression analysis resulted in 68 differentially expressed genes between RASFsn-stimulated and NDSFsn-
stimulated chondrocytes: 44 genes were induced and 24 genes were repressed. Differentially expressed genes were functionally categorized into 
six rheumatoid arthritis-relevant groups and are listed with accession number, mean fold change in expression and mean signal intensity 
(generated by GCOS and RMA). Annotation of mean signal intensity of RASFsn-stimulated and NDSFsn-stimulated chondrocytes could facilitate 
the identification of potential rheumatoid arthritis-specific genes for which further investigation may be required. The mean signal intensity of 
unstimulated chondrocytes is listed for the determination of baseline expression.
Bcl2, B-cell leukemia 2; cig5, cytomegalovirus-inducible gene 5; ECM, extracellular matrix; Gro, growth-related oncogene; HGF, hepatocyte 
growth factor; HLH, helix–loop–helix; MIP, macrophage inflammatory protein.
Table 1 (Continued)
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Protein membrane arrays of synovial fibroblast 
supernatants
RASFsn-stimulated chondrocytes showed a substantial differ-
ential expression of genes that were associated with inflamma-
tion and cartilage destruction as determined by microarray
analysis and real-time RT-PCR. As shown previously, genome-
wide microarray analysis of the respective RASF determined a
disease-related expression profile of distinct inflammatory
mediators [23]. We therefore hypothesized that soluble medi-
ators were secreted from RASF into the supernatant (RAS-
Fsn) and induced the catabolic and inflammatory response of
chondrocytes after stimulation. Protein analysis of the super-
natant of RASF was used to analyze the secretion of soluble
mediators by RASF with the use of custom antibody-based
cytokine membrane arrays. A proteomic analysis of these
supernatants revealed an increased secretion of cytokines/
Table 2
Differentially expressed genes in RASFsn-stimulated chondrocytes (FC ≥ 1,5; FC ≤ -1,5; GCOS)
Functional annotation: gene title (gene 
symbol)
Accession no. Chondrocyte mean 
fold change in 
expression (GCOS 
analysis)
Chondrocyte mean signal intensity (GCOS analysis)
RASFsn versus 
NDSFsn stimulation
RASFsn stimulation NDSFsn stimulation No stimulation
Inflammatory/catabolic mediators
Catalase (CAT) NM_001752.1 -1.7 672.85 1,221.90 1,386.65
Chemokine (C-C motif) ligand 5 
(RANTES)
NM_002985.1 4.1 103.40 25.20 18.95
Chemokine orphan receptor 1 
(CMKOR1)
AI817041 2.2 609.45 322.55 89.50
Glutathione peroxidase 3 (GPX3) AW149846 -1.5 1,083.25 1,617.75 669.90
Interleukin-1β (IL-1β) M15330 2.2 91.80 34.10 36.45
Interleukin-6 (IL-6) NM_000600.1 2.6 10,058.00 4,907.15 56.25
Nuclear factor-κB associated gene 
(NF-κB1)
NM_003998.1 1.5 472.80 312.10 176.75
Nuclear factor-κB associated gene 
(NF-κB2)
BC002844.1 2.3 125.75 48.25 41.50
Prostaglandin E synthase (PGES) NM_004878.1 1.9 1,308.70 596.10 123.10
TNF-α-inducible protein 2 (TNFAIP2) NM_006291.1 2.6 337.65 109.90 98.90
Tumor necrosis factor receptor 
(TNFRSF1B)
NM_001066.1 2.3 439.20 197.70 67.10
ECM degradation
Matrix metalloproteinase 10 (MMP10) NM_002425.1 2.7 587.60 233.90 20.05
Matrix metalloproteinase 12 (MMP12) NM_002426.1 5.2 161.40 25.90 18.00
ECM formation
Collagen, type I, α1 (COL1A1) NM_000088.1 -2.3 472.15 1,182.40 6,603.50
Collagen, type V, α1 (COL5A1) N30339 -1.9 143.80 296.95 862.60
Collagen, type X, α1 (COL10A1) X98568 -4.6 36.50 163.90 5.00
Collagen type XI, α1 (COL11A1) J04177 -1.7 565.80 982.25 1,146.10
Testican-1 NM_004598 -1.8 543.80 1,384.10 2,311.00
Expression levels of rheumatoid arthritis-relevant genes that failed to reach the twofold regulation criteria for both GCOS and RMA statistical 
analyses are shown. Expression for all listed genes showed a reproducible regulation as determined by GCOS analysis. Genes were functionally 
categorized into inflammatory/catabolic mediators and genes involved in the degradation and formation of extracellular matrix (ECM), and are 
listed with accession number, mean fold change in expression (GCOS) and mean signal intensity (GCOS). Mean signal intensity of unstimulated 
chondrocytes is listed for the determination of baseline expression. The expression was not reproducibly changed for MMPs and collagens that 
are not listed in this table.
ECM, extracellular matrix; GCOS, GeneChip Operating Software; NDSFsn, supernatant of synovial fibroblast cell line derived from a normal 
donor; RASFsn, supernatant of synovial fibroblast cell line derived from a patient with rheumatoid arthritis; RMA, Robust Multi-array Analysis; 
TNFRSF1B, tumor necrosis factor receptor superfamily, member 1B.Available online http://arthritis-research.com/content/10/1/R9
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chemokines by RASF (Figure 4); the secretion of IL-6 (spots
G3 and G4), CXCL8 (IL-8; spots H3 and H4), monocyte che-
moattractant protein-1 (CCL2/MCP-1; spots I3 and I4) and
CXCL1–3 (Gro; spots I1 and I2) was increased compared
with NDSF. Because cultivation was performed in medium
containing serum, the protein content of cultivation medium
supplemented with 10% human serum was analyzed as a
control.
Discussion
To our knowledge, this is the first study that has determined
the genome-wide molecular expression pattern of human
chondrocytes in response to stimulation with RASFsn and
thus provided comprehensive insight into chondrocyte dys-
function during RA-related destruction of cartilage.
RASF are considered to produce a variety of chemokines and
catabolic/inflammatory mediators that recruit immune cells to
the site of inflammation and facilitate the progressive destruc-
tion of articular cartilage [3]; the interaction between both cell
types therefore has a fundamental role in RA-related destruc-
tion of cartilage. We therefore established an interactive
model in vitro that determines RA-related molecular processes
in chondrocytes induced by soluble mediators that were
secreted from RASF. In this model, the chondrocyte alginate
bead culture was chosen because it offers the opportunity to
culture, in three dimensions, expanded human chondrocytes in
a phenotype-stabilizing environment and at the same time to
allow interactive culture of chondrocytes and RASF by stimu-
lating cartilage-like cultures with supernatant of RASF (RAS-
Fsn). Because direct cell contact between chondrocytes and
RASF was not provided, a genome-wide molecular response
of chondrocytes to soluble synovial mediators could be deter-
mined by microarray analysis.
In previous studies, the respective RASF showed a disease-
related expression pattern as determined by genome-wide
expression analysis. Moreover, treatment with frequently used
anti-rheumatic drugs reverted the expression of numerous RA-
related genes [23]; RASF can therefore be considered to be
a representative of activated SF. Beyond the RA-relevant
expression characteristics, the synovial cell line facilitates
standardization, availability and comparability that are appro-
priate for studies in vitro.
In the present study, analysis of protein secretion determined
the release of distinct inflammatory mediators; the synthesis of
IL-6, CXCL8 (IL-8), CCL2 (MCP-1) and CXCL1–3 (Gro) was
increased in RASF compared with NDSF and serum control
(Figure 4). This is in line with elevated levels of CXCL8 in
supernatants of RASF compared with NDSF as shown by
enzyme-linked immunosorbent assay [23]. RASF have already
been identified as significant producers of IL-6 and CXCL8.
Expression of IL-6 in synovial fluid correlates with markers of
inflammation, and blockade of IL-6 signaling is effective in pre-
vention and treatment in models of inflammatory arthritis
[31,32]. IL-6 and its soluble receptor have previously been
reported to repress important cartilage-specific matrix genes,
namely proteoglycans, by means of STAT signaling pathways
[33]. In addition, the inflammatory mediators CCL2 and
CXCL1–3 have already been identified as being induced in IL-
1β-stimulated RASF; CCL2 acting through chondrocyte
CCR2 has been described to induce MMP expression and to
inhibit proteoglycan synthesis [34].
Figure 3
Validation of gene expression of stimulated chondrocytes by real-time RT-PCR Validation of gene expression of stimulated chondrocytes by real-time RT-PCR. Semi-quantitative real-time RT-PCR of selected genes that were dif-
ferentially expressed in chondrocytes stimulated with supernatant of a synovial fibroblast cell line derived from a patient with rheumatoid arthritis 
(RASFsn) as determined by microarray analysis was performed. Real-time RT-PCR gene expression analysis determined that the expression of 
cyclooxygenase-2 (COX-2), interferon-α inducible protein-6–16 (IFI-6–16) and chemokine (C-X-C motif) receptor 4 (CXCR4) was significantly 
induced during stimulation of cartilage-like cultures with RASFsn compared with stimulation with supernatant of a synovial fibroblast cell line derived 
from normal donor (NDSFsn). The gene expression of steroid sulfatase (STS), chondroitin sulfate proteoglycan 2 (CSPG2), cartilage oligomeric 
matrix protein (COMP) and thioredoxin interacting protein (TXNIP) was significantly repressed during stimulation with RASFsn. Consistent changes 
were observed between real-time RT-PCR and microarray analysis for all genes examined. The expression of selected genes was calculated as the 
percentage of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression. The mean of each triplicate well of both experimental groups is 
plotted and the error bars represent SD. For statistical analysis, Students t-test was applied (*, P ≤ 0.05; ***, P ≤ 0.001).Arthritis Research & Therapy    Vol 10 No 1    Andreas et al.
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Strikingly, the amount of inflammatory mediators such as
CXCL8 is increased in NDSF supernatant compared with
serum control. However, the sensitivity of the protein mem-
brane array is very high for CXCL8, ranging from 1 to 25 pg/
ml and it thus detects even very small amounts of protein. The
secretion of inflammatory cytokines from NDSF may be due to
cultivation of the SF in medium supplemented with human all-
ogenic serum or it may be due to transfection with SV40T. The
human serum pool that we used contained detectable
amounts of proinflammatory mediators (IL-1β and TNF-α; Fig-
ure 4) that may themselves have induced the proinflammatory
response in NDSF. Moreover, immortalization with SV40T has
been shown to induce the basal expression level of CXCL8 in
immortalized SF compared with parental cells [35]. Further-
more, the serum control was characterized by a high content
of intercellular cell adhesion molecule-1 (ICAM-1), epidermal
growth factor (EGF), CCL5/RANTES and MMP-9 that was,
surprisingly, not reflected in SF-conditioned medium. Because
all supernatants including the serum control were subjected to
the same conditions, the altered protein pattern is most prob-
ably due to interaction of the respective proteins with the SF,
such as specific binding to cell surface receptors, proteolytic
degradation and cell metabolism, or binding of proteins to
ECM components on the cellular surface.
An interesting finding was the identification of functional gene
groups that are differentially expressed between RASFsn-
stimulated and NDSFsn-stimulated chondrocytes (Tables 1
and 2). Gene expression profiling of unstimulated
chondrocytes determined the chondrocyte baseline expres-
sion of these RA-relevant genes, indicating that SF themselves
have an impact on chondrocyte gene expression. However,
Figure 4
Proteomic membrane analysis of synovial fibroblast supernatants Proteomic membrane analysis of synovial fibroblast supernatants. (a) Comprehensive protein membrane array map. The human protein array simulta-
neously profiles 30 proteins in duplicate, a set of six positive controls and four negative controls. EGF = epidermal growth factor; GCSF = granulo-
cyte colony stimulating factor; Gro = growth-related oncogene; HGF = hepatocyte growth factor; ICAM-1 = intercellular cell adhesion molecule-1; 
IFN-γ = interferon-γ; IGF-1 = insulin-like growth factor-1; IGFBP-3, 4 = insulin-like growth factor binding protein-3, 4; IL-1α, 1β, 6, 8 = interleukin-1α, 
1β, 6, 8; IL-1ra = interleukin-1 receptor antagonist; MCP-1 = monocyte chemoattractant protein-1; MIP-1α, 1β, 3α = macrophage inflammatory pro-
tein-1α, 1β, 3α; MMP-1, 3, 9, 13 = matrix metalloproteinase-1, 3, 9, 13; Neg = negative control; pos = positive control; RANTES = regulated on 
activation, normal T cell expressed and secreted; SDF-1 = stromal cell derived factor-1; TGF-β3 = transforming growth factor-β3; TNF-α = tumor 
necrosis factor-α; VCAM-1 = vascular cell adhesion molecule-1; VEGF = vascular endothelial growth factor. The sensitivity of antibodies of the Ray-
Bio™ human array for the respective proteins differs; proteins in italics: high sensitivity (1–25 pg/ml), in bold: medium sensitivity (100 – 300 pg/ml), 
underlined: low sensitivity (1,000 – 10,000 pg/ml), Gro determines Groα (low sensitivity) and Groβ (low sensitivity) and Groγ (high sensitivity). (b) 
Supernatants of a synovial fibroblast cell line derived from a patient with rheumatoid arthritis (RASF) and a synovial fibroblast cell line derived from a 
normal donor (NDSF) were examined for cytokine secretion with the use of antibody-based protein arrays. Because cultivation was performed in 
medium supplemented with serum, the protein content of the cultivation medium was analyzed as a control. Results are shown after exposure of the 
array membranes to X-ray films for 2 minutes. The cytokines/chemokines IL-6, CXCL8 (IL-8), monocyte chemoattractant protein-1 (MCP-1), and 
growth-related oncogene (Gro) showed increased secretion from RASF compared with NDSF and with serum control.Available online http://arthritis-research.com/content/10/1/R9
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RASFsn-stimulated chondrocytes are supposed to represent
the 'diseased' state, and comparison with the 'healthy' state of
NDSFsn-stimulated chondrocytes was used to determine the
chondrocyte RA-relevant gene expression pattern independ-
ently of SF regulation.
RASFsn-stimulated chondrocytes showed, in comparison with
NDSF stimulation, a regulated expression of genes associated
with inflammation (NF-κB signaling, cytokines/chemokines
and receptors, immune response) and cartilage destruction
(MMPs, chondrocyte apoptosis, suppressed matrix synthesis).
Selected differentially expressed genes are illustrated in Fig-
ure 5 and printed in black; genes and text in grey are hypothet-
ical assumptions for the established in vitro model according
to the literature and still require further validation.
Representing the inflammatory aspect, A2A adenosine recep-
tor (ADORA2A) was induced and is known to be involved in
the lipopolysaccharide-induced expression of inducible nitric
oxide synthase in chondrocytes, and inducible nitric oxide syn-
thase is a major source of intra-articular production of nitric
oxide [36]. Nitric oxide has been described to contribute sig-
nificantly to chondrocyte death and progressive cartilage
destruction by decreasing the synthesis of proteoglycan and
Figure 5
Molecular pathways of rheumatoid arthritis-related cartilage destruction as reflected by the in vitro model Molecular pathways of rheumatoid arthritis-related cartilage destruction as reflected by the in vitro model. Illustration of differentially expressed 
genes of chondrocytes stimulated with supernatant of synovial fibroblast cell line derived from a patient with rheumatoid arthritis (RASFsn) com-
pared with stimulation with supernatant of synovial fibroblast cell line derived from a normal donor (NDSFsn); induced genes were printed in bold, 
repressed genes in italics. Genes and text in grey are hypothetical assumptions of the established in vitro model for which further validations are still 
required. Cartilage destruction in rheumatoid arthritis was characterized by a disturbed homeostasis of chondrocyte function that leads to an 
enhanced cartilage catabolism involving extracellular matrix degradation via matrix metalloproteinases and suppressed extracellular matrix synthesis, 
induction of catabolic cytokines/chemokines and proinflammatory inducible enzymes, and activation of NF-κB signaling pathway. Thus, the estab-
lished tissue model provided profound insights into the molecular processes involved in rheumatoid arthritis-related cartilage destruction regarding 
chondrocyte gene expression patterns. ADORA2A, adenosine A2A receptor; CMKOR, chemokine orphan receptor; COLL11A1, collagen type XI, 
α1; COMP, cartilage oligomeric matrix protein; COX, cyclooxygenase; CSPG, chondroitin sulfate proteoglycan; iNOS, inducible nitric oxide syn-
thase; MMP, matrix metalloproteinase; NO, nitric oxide; PGs, prostaglandins; PGES, prostaglandin E synthase; RASF, synovial fibroblast cell line 
derived from patient with RA; RIPK, receptor-interacting serine/threonine kinase; SMS, spermine synthase; STAT, signal transduction and activators 
of transcription; THBS, thrombospondin; TLR, toll-like receptor; TXNIP, thioredoxin interacting protein.Arthritis Research & Therapy    Vol 10 No 1    Andreas et al.
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collagen type II [37-39], mediating cytokine-dependent sus-
ceptibility to oxidant injury [40] and inducing apoptosis [41].
Besides ADORA2A, the expression of COX-2 as an important
pharmacological target gene of inflammation was induced.
The formation of prostaglandins by COX-2  is a prominent
inflammatory process; inhibition of COX-2 has cartilage-pro-
tective properties, because specific COX-2 inhibitors (such as
celecoxib) have already facilitated distinct advances in RA
therapy [42]. Expression of PGES, which is involved in the
synthesis of prostaglandin E2 downstream of COX-2, was
induced in RASFsn-stimulated chondrocytes. PGES  has
already been reported to be induced in chondrocytes after
proinflammatory stimuli and mechanical stress [43,44]. As
shown here, this is consistent with the induction of COX-2,
PGES and MMP genes in human chondrocytes cultured in
alginate and stimulated with supernatants of RASF.
Furthermore, NF-κB-activating genes were induced in RAS-
Fsn-stimulated chondrocytes, including RIPK2, TLR2, the NF-
κB-associated genes NF-κB1 and NF-κB2, and SMS. Pro-
moters of numerous genes involved in inflammation and MMP
expression show NF-κB-binding sites [45-47]; NF-κB-
dependent genes may therefore be prominent drug targets in
RA therapy. RIPK2 has been shown to mediate TNF-α-
induced NF-κB activation and induction of apoptosis [48,49].
The induction of numerous cytokines/chemokines fits into the
scenario of molecular changes occurring in RA cartilage.
Although mature articular cartilage shows little metabolic
activity, chondrocytes have previously been described to
secrete numerous cytokines/chemokines and chemokine
receptors that induce the release of matrix-degrading enzymes
and enhance cartilage catabolism [50-52]. RASFsn-stimu-
lated chondrocytes showed an increased expression of
CXCL1–3  (growth-related oncogene α-γ; Groα-γ), CXCL8
(IL8), CCL20 (macrophage inflammatory protein-β; MIP-1β)
and the chemokine receptor CXCR4.  CXCL1  has been
described to initiate apoptosis in osteoarthritis chondrocytes
and induces MMP-3 secretion acting through CXCR2 [53];
CXCL8 has powerful neutrophil chemotactic properties [54],
and  CXCR4  and  CCL20  enhance the release of matrix-
degrading enzymes [50,55,56]. Inflammatory cytokines that
have already been established as markers for RA-related
destruction of cartilage, such as IL-1β and IL-6, were differen-
tially expressed in stimulated chondrocytes. Apart from the dif-
ferential expression of numerous cytokines/chemokines,
RASFsn-stimulated chondrocytes showed a decreased
expression of genes protecting the cell from oxidative damage
(catalase and glutathione peroxidase 3).
Furthermore, genes directly involved in ECM composition,
such as COMP, CSPG2, numerous collagens and THBS2,
are repressed in RASFsn-stimulated chondrocytes, that char-
acterizes cartilage destruction in RA as a distinct suppression
of chondrocyte ECM synthesis. Contributing to RA-related
ECM turnover, the expression of MMP10, MMP12 and chem-
okine orphan receptor 1 (CMKOR1) was induced in RASFsn-
stimulated chondrocytes. MMP10 expression in chondrocytes
after cytokine stimulus contributes significantly to collagen
breakdown and thus to cartilage degradation [57], and overex-
pression of MMP12 in transgenic rabbits has been shown to
facilitate the development of inflammatory arthritis [58].
Treatment of human primary osteoarthritis chondrocytes with
CMKOR1 agonists has previously been reported to induce
matrix degradation and MMP activity, suggesting an important
role in the development of osteoarthritis [59]. In addition, tes-
tican 1, an inhibitor of MMP activation that has been described
as having an important role in matrix turnover in osteoarthritis
cartilage, was repressed in RASFsn-stimulated chondrocytes
[60]. However, neither CMKOR1 nor testican-1 has yet been
described for RA-cartilage turnover.
In summary, our microarray data determined key regulatory
molecules of RA-related destruction of cartilage that are con-
sistent with already established marker molecules or that have
not yet been determined. As we have established an in vitro
model that abstracts in vivo tissue features, some regulations
expected for cartilage destruction, such as a decreased
expression of collagen type II or an increased expression of
collagenases, were not observed. However, we consider our
data to be convincing because the induction of major media-
tors of inflammation (COX-2, PGES, ADORA2A, IL-1β, IL-6,
CXCL8 and CXCR4) and cartilage destruction (MMP10 and
MMP12) and the repression of key ECM components (COMP
and  CSPG2) are most probably important reasons for
chondrocyte dysfunction in RA-related destruction of
cartilage.
Because direct cell attachment of SF to chondrocytes was not
provided, soluble mediators secreted from RASF regulated
the expression of chondrocyte genes and thus disturbed the
catabolic–anabolic homeostasis of mature cartilage function.
Although the attachment of RASF to cartilage is a significant
feature of RA-related destruction of cartilage in comparison
with other non-destructive forms of arthritis, direct cell contact
between chondrocytes and RASF seems not to be necessarily
required for the destructive modulation of chondrocyte
function.
Conclusion
The present study provides a comprehensive insight into the
RA-related destruction of cartilage on the basis of chondro-
cyte gene expression pattern involving marker genes of inflam-
mation and cartilage destruction. We identified molecules
already known to be involved in RA-related destruction of car-
tilage; remarkably, we detected the expression of genes not
previously associated with RA chondrocyte dysfunction. Thus,
the established in vitro model emerged to determine the spe-
cific role of distinct genes in the pathogenesis of cartilageAvailable online http://arthritis-research.com/content/10/1/R9
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destruction in RA and may disclose potent pharmacological
targets for cartilage regeneration and repair.
Therefore, this in vitro model may help in understanding the
molecular effects of anti-rheumatic pharmaceuticals on carti-
lage regeneration and may facilitate the identification of puta-
tive pro-cartilage substances. Because SF treated with
frequently used anti-rheumatic drugs showed a reversion of
the gene expression of typical RA-related genes [23], a
hypothesized drug-related change in the synthesis of disease
mediators in RASF may affect the expression in chondrocytes
of RA-related target genes of cartilage destruction, demon-
strating the molecular effects of anti-rheumatic pharmaceuti-
cals and putative pro-cartilage substances on cartilage
regeneration and repair.
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